Attention is focusing on whether Cinqair, an asthma antibody drug, will be listed on the list of insurance benefits after six years of domestic approval. According to related industries, Teva Handok is negotiating with the NHIS for the listing of Cinqair, a monoclonal antibody targeting interleukin (IL)-5. Unlike competitive drugs, positive results are expected as the general listing process is in progress, rather than RSA.

AstraZeneca Korea's Fasenra and GSK Korea's Nucala, two interleukins (IL)-5 antagonists with the same mechanism as Cinqair, are aiming to enter reimbursement rights through RSA, but no progress has been made in discussions yet. These drugs reduce the number of eosinophils, a type of